Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 3/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269403 | 0.88 | PTPN1 (0.49) | PTPN1MEN1KMT2AALDH1A1PTPRC | |
| SCHEMBL590493 | 0.88 | PTPN1 (0.49) | PTPN1MEN1KMT2AALDH1A1PTPRC | |
| SCHEMBL27815145 | 0.77 | ALDH1A1 (0.45) | PTPN1MEN1KMT2AALDH1A1PTPRC | |
| SCHEMBL6806279 | 0.76 | KMT2A (0.54) | PTPN1MEN1KMT2AALDH1A1KCNN4 | |
| SCHEMBL8386738 | 0.75 | ALDH1A1 (0.43) | PTPN1KMT2AALDH1A1CETPPTPRC | |
| SCHEMBL5400501 | 0.74 | KMT2A (0.51) | PTPN1MEN1KMT2AALDH1A1KCNN4 | |
| SCHEMBL11807375 | 0.74 | KMT2A (0.51) | PTPN1MEN1KMT2AALDH1A1KCNN4 | |
| SCHEMBL27793760 | 0.73 | CETP (0.42) | PTPN1KMT2AALDH1A1CETPPTPRC | |
| SCHEMBL2269978 | 0.73 | ALDH1A1 (0.53) | KMT2AALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL29255120 | 0.72 | KMT2A (0.50) | PTPN1MEN1KMT2AALDH1A1KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | PTPN1 427/4885MEN1 1285/4885KMT2A 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.